Continuing Medical & Nurse Education: Hand Involvement in Scleroderma

Hand Involvement in Scleroderma: Early Diagnosis and Management

Course Director: Flavia v. Castelino, M.D.
Release Date: 07/07/2023
Expiration Date: 07/07/2024

  • Credits Available:
    • A few Examples include the following:
      • Physicians – Maximum of 1 AMA PRA Category 1 CreditTM
      • Registered Nurses – 1.0 contact hour
  • Jointly provided by Postgraduate Institute for Medicine and National Scleroderma Foundation 

Accreditation Information

Hand Involvement in Scleroderma: Early Diagnosis and Management

Jointly provided by the Postgraduate Institute for Medicine and National Scleroderma Foundation

Multiple grantors: Supported by independent educational grants provided by Boehringer Ingelheim & Janssen Pharmaceuticals Companies of Johnson & Johnson US

Release Date: 07/07/2023

Available for credit until 07/07/2024

The estimated time to complete this activity is 1 hour(s).

Link to Course:



Flavia v. Castelino, M.D.
Director, Scleroderma Program, Massachusetts General Hospital
Harvard Medical School, Massachusetts General Hospital

Michael R. York, M.D.
Professor of Medicine
Scleroderma Program, Boston University Medical

Target Audience

This activity is intended for Physicians & Registered Nurses engaged in the care of patients with Systemic Scleroderma.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Understanding the pathophysiology underlying digital vascular disease in SSc
  • Overview of currently available medical therapies for Raynaud’s phenomenon and digital ulcers in SSc
  • Discuss novel treatments for digital vascular disease in SSc


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and      National Scleroderma Foundation.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

If AMA PRA Category 1 Credit is offered:

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this [enduring material][journal-based CME activity][test-item writing activity][manuscript review activity][PI CME activity][internet point-of-care activity] for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

If ANCC credit is offered:

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours. (If applicable, for APRNs, enduring activity) Designated for ___ contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Flavia v. Castelino, M.D.
Consulting fees from: Boehringer Ingelheim
Grant funding from: Mitsubishi Tanabe, Kadman, Prometheus

Michael R. York, M.D.

The PIM planners and others have nothing to disclose. The National Scleroderma Foundation planners and others have nothing to disclose.

Fee Information

There is no fee for this educational activity.

Instructions for Obtaining Credit

During the period of accreditation, participants must 1) read the learning objectives and disclosures; 2) study the educational content; and 3) complete the post-test (if applicable) and the evaluation form.  To answer the questions, click on your selected choice for each answer and then proceed to the next question.  If applicable, your post-test will automatically be graded.  After successfully completing these items, your certificate will be made available immediately.  Click on View Certificate, and print or download the certificate for your records.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Computer System Requirements

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome).  Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content.  These activities will be marked as such and will provide links to the required software.  That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.